SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported): January
30, 2007
CYTORI
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-32501
|
33-0827593
|
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification Number)
|
3020
Callan Road, San Diego, California 92121
(Address
of principal executive offices, with zip code)
(858)
458-0900
(Registrant's
telephone number, including area code)
n/a
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
| o |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
| o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
| o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
5.02 Departure of Directors or Principal
Officers; Election of Directors; Appointment of Principal Officers; Compensatory
Arrangements of Certain Officers
(e)
On
January 30, 2007, our Compensation Committee awarded the following cash bonuses
to our named executive officers pursuant to our 2006 Executive Management
Incentive Compensation plan, which provides for such bonuses based upon the
corporate and individual achievements of specified objective performance
goals
for the year:
Christopher
Calhoun, CEO
Bonus
Awarded: $121,800
Marc
Hedrick, President
Bonus
Awarded: $84,863
Mark
Saad, Chief Financial Officer
Bonus
Awarded: $63,438
Seijiro
Shirahama, Senior Vice President - Asia Pacific
Bonus
Awarded: $36,425
John
Ransom, PhD, Vice President of Research - Regenerative Cell
Technology
Bonus
Awarded: $24,000
We
expect
Mr. Calhoun, Dr. Hedrick, Mr. Saad, Mr. Shirahama and Dr. Ransom to be our
“named executive officers” by virtue of their status as our Principal Executive
/ Principal Financial Officers, and/or based upon their total compensation
received for fiscal 2006.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| CYTORI THERAPEUTICS, INC. | |
| Date: February 5, 2007 | By: /s/ Mark E. Saad |
|
Mark
E. Saad
Chief
Financial
Officer
|
3